A single-arm, open-label, proof-of-concept study is underway in the Netherlands to investigate the effect of the HDAC inhibitor vorinostat in patients with BRAF V600E-mutated resistant melanoma (NCT02836548) [247]. This evidence concerns the gene HDAC9 and melanoma.